Chest
Volume 147, Issue 2, February 2015, Pages 520-528
Journal home page for Chest

Original Research: Chest Infections
Optimal Duration of Anti-TB Treatment in Patients With Diabetes: Nine or Six Months?

https://doi.org/10.1378/chest.14-0918Get rights and content
Under a Creative Commons license
open access

BACKGROUND

Diabetes mellitus (DM) increases the risk of TB recurrence. This study investigated whether 9-month anti-TB treatment is associated with a lower risk of TB recurrence within 2 years after complete treatment than 6-month treatment in patients with DM with an emphasis on the impact of directly observed therapy, short course (DOTs).

METHODS

Patients with pulmonary but not extrapulmonary TB receiving treatment of 173 to 277 days between 2002 and 2010 were identified from the National Health Insurance Research Database of Taiwan. Patients with DM were then selected and classified into two groups based on anti-TB treatment duration (9 months vs 6 months). Factors predicting 2-year TB recurrence were explored using Cox regression analysis.

RESULTS

Among 12, 688 patients with DM and 43, 195 patients without DM, the 2-year TB recurrence rate was 2.20% and 1.38%, respectively (P < .001). Of the patients with DM, recurrence rate decreased from 3.54% to 1.19% after implementation of DOTs (P < .001). A total of 4, 506 (35.5%) were classified into 9-month anti-TB treatment group. Although a 9-month anti-TB treatment was associated with a lower recurrence rate (hazard ratio, 0.76 [95% CI, 0.59-0.97]), the benefit disappeared (hazard ratio, 0.69 [95% CI, 0.43-1.11]) under DOTs. Other predictors of recurrence included older age, male sex, malignancy, earlier TB diagnosis year, culture positivity after 2 months of anti-TB treatment, and anti-TB treatment being ≤ 80% consistent with standard regimen.

CONCLUSIONS

The 2-year TB recurrence rate is higher in a diabetic population in Taiwan and can be reduced by treatment supervision. Extending the anti-TB treatment by 3 months may also decrease the recurrence rate when treatment is not supervised.

ABBREVIATIONS

CDC
Centers for Disease Control
DM
diabetes mellitus
DOTs
directly observed therapy, short course
DST
drug susceptibility test
HbA1c
glycated hemoglobin
HR
hazard ratio
ICD-9-CM
International Classification of Diseases, 9th Revision, Clinical Modification
NHIRD
National Health Insurance Research Database

Cited by (0)

FUNDING/SUPPORT: This study was supported by the National Science Council, Taiwan [Grant NSC 99-2314-B-002-088-MY2] and the Centers for Disease Control, Taiwan [Grant DOH-101-DC-1101].

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted use, distribution, and reproduction to noncommercial entities, provided the original work is properly cited. Information for reuse by commercial entities is available online.